Table 2. Correlations between baseline characteristics and pSTAT3 fluorescence intensity of lymphocyte subsets and monocytes at baseline.
| CD4+ | CD8+ | CD19+ | CD14+ | |
|---|---|---|---|---|
| r (95% CI) | r (95% CI) | r (95% CI) | r (95% CI) | |
| Age | 0.26 (-0.17 to 0.65) | 0.20 (-0.22 to 0.62) | -0.01 (-0.47 to 0.45) | -0.01 (-0.42 to 0.42) |
| Duration of symptoms | -0.28 (-0.60 to 0.10) | -0.03 (-0.41 to 0.36) | 0.33 (-0.03 to 0.70) | 0.06 (-0.31 to 0.43) |
| RF | 0.21 (-0.11 to 0.52) | 0.03 (-0.30 to 0.37) | 0.10 (-0.27 to 0.48) | 0.37 (-0.02 to 0.67) |
| DAS28 | 0.42* (0.10 to 0.77) | 0.21 (-0.21 to 0.65) | -0.02 (-0.45 to 0.42) | 0.26 (-0.18 to 0.69) |
| Erythrocyte sedimentation rate | 0.30 (-0.06 to 0.66) | 0.08 (-0.30 to 0.47) | -0.26 (-0.70 to 0.18) | 0.10 (-0.34 to 0.53) |
| Serum C-reactive protein | 0.29 (-0.08 to 0.66) | 0.20 (-0.16 to 0.55) | -0.27 (-0.69 to 0.16) | 0.09 (-0.33 to 0.51) |
| Number of swollen joints, 0–66 | 0.23 (-0.18 to 0.63) | 0.05 (-0.39 to 0.49) | 0.19 (-.26 to 0.63) | 0.28 (-0.20 to 0.75) |
| Number of tender joints, 0–68 | 0.25 (-0.14 to 0.63) | 0.18 (-0.25 to 0.61) | 0.26 (-0.13 to 0.65) | 0.33 (-0.10 to 0.76) |
| Patient’s global assessment, 0-100mm VAS | -0.01 (-0.44 to 0.42) | -0.18 (-0.62 to 0.25) | -0.05 (-0.45 to 0.35) | -0.12 (-0.51 to 0.26) |
| Erosion score † | 0.44* (0.14 to 0.73) | 0.62*** (0.40 to 0.85) | 0.55** (0.28 to 0.82) | 0.42* (0.13 to 0.71) |
| Plasma IL-6 | 0.45* (0.07 to 0.84) | 0.07 (-0.38 to 0.52) | 0.13 (-0.28 to 0.53) | 0.41* (0.08 to 0.73) |
| Plasma IL-17 | 0.33 (-0.04 to 0.71) | 0.26 (-0.19 to 0.71) | 0.42* (0.04 to 0.80) | 0.40 (-0.01 to 0.80) |
| Plasma IL-21 | 0.40* (0.06 to 0.74) | 0.48* (0.17 to 0.80) | 0.64*** (0.32 to 0.96) | 0.68*** (0.48 to 0.89) |
Abbreviations: CI = confidence interval, r = Spearman correlation coefficient, for other abbreviations see Table 1.
†Number of eroded joints in radiographs of hands and feet.
*p<0.05
**p<0.01
***p<0.001.